News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Boehringer Ingelheim Corporation Release: Recruitment Complete for Trajenta ® (linagliptin) Cardiovascular Outcome Study in Patients With Type 2 Diabetes


11/8/2012 9:53:31 AM

INGELHEIM, Germany--(BUSINESS WIRE)--For Non-U.S. and Non-U.K. Media -- Boehringer Ingelheim and Eli Lilly and Company are pleased to announce that the recruitment of patients for CAROLINA (Cardiovascular Outcome Study of Linagliptin versus Glimepiride in Patients with Type 2 Diabetes)1 has been completed. Linagliptin is currently the only DPP-4 inhibitor that is being compared to an active comparator in a long-term prospective cardiovascular (CV) outcome study. “CAROLINA has the potential to be a landmark study as it will evaluate cardiovascular safety of linagliptin compared to the sulphonylurea glimepiride. This is the first time a DPP-4 inhibitor is being directly compared to the sulphonylurea class in a long-term cardiovascular outcome study,” said Prof. Julio Rosenstock, Director of the Dallas Diabetes and Endocrine Center, Texas, and Principle Investigator of the study. “Sulphonylureas are the most frequently used add-on therapy to metformin, which is considered the standard first-line therapy. Therefore, the results of CAROLINA could potentially have a significant impact on clinical practice.”

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES